Analytical Data
-
Gene name
F2
- Application
-
Alternative Names
FII; TM; PT; Thrombin; Prothrombin; Pro-Thrombin; Activation peptide fragment 1; Activation peptide fragment 2
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P18292
-
Expression Region
Ser201~Arg323
-
Molecular Weight
20kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of F2 recombinant proteins has gained significant attention in recent years due to their potential applications in biotechnology and medicine. F2 proteins are derived from various biological sources, often modified for enhanced functionality or specificity. They play a crucial role in a range of applications, including vaccine development, therapeutic interventions, and diagnostic tools. The F2 paradigm involves the engineering of proteins to exhibit desired characteristics, such as improved stability, increased binding affinity, or targeted delivery mechanisms. Advances in recombinant DNA technology, coupled with high-throughput screening methods, have facilitated the rapid optimization of these proteins. Researchers have particularly focused on F2 proteins for their ability to elicit strong immune responses, making them promising candidates for next-generation vaccines against viruses, bacteria, and cancer. Additionally, the use of F2 proteins in targeted drug delivery systems showcases their versatility and potential to revolutionize treatment modalities. As understanding of protein structure and function continues to evolve, the prospects for F2 recombinant proteins in therapeutic and diagnostic applications appear increasingly promising, paving the way for innovative solutions to complex medical challenges.
